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Ketamine for Depression:
A Mixed-Methods Study
Philip E. Wolfson

Center for Transformational Psychotherapy
San Francisco and San Anselmo, CA, USA
Prior studies have reported variously on the presence or absence of dissociative effects at
subanesthtetic doses of ketamine administered for treatment-resistant depression. This mixedmethods study emulated the protocol used for the studies in question, with IV administration
of 0.5mg/kg over 40 minutes with eight experienced ketamine users. Quantitative measures
were generally insignificant since this was not a population reporting depression; blood
pressure increased as expected by 20-30mm systolic and 6-20mm diastolic, falling rapidly
by 20 minutes after completion of the infusion. Individual qualitative reports reports of
relaxation, pleasant sensation, decreased cognitive function, and some disabling of ordinary
capacities. As experienced users, subjects commented freely on what was characterized as
the triviality of the experience, and typically expressed skepticism that ketamine could
have antidepressant properties when administered at this dose or in this manner, as well as
disbelief that it could be beneficial except perhaps as a period of relaxation, or as a partial
break from ordinary states of mind in naïve subjects. Group discussion produced a consensus
recommendation in favor of threshold- and higher-dosage transformative work beginning
with a 40-50mg IM bolus, potentially in a series of sessions with higher dosages if indicated,
with the number of sessions to be determined by clinical practice; such work should occur
in a closely monitored psychotherapeutic setting.
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etamine is a dissociative anesthetic that has
recently shown potential as a significant new
antidepressant (Duman & Agajanian, 2012).
Unlike existing antidepressants that target serotonin,
norepinephrine, and dopamine systems--and that may
take a number of weeks to achieve efficacy, ketamine is
an NMDA receptor antagonist that affects the glutamate
system and appears to provide significant relief to some
individuals within only hours or days (Ryan, Marta, &
Koek, 2014 [this issue]). These findings are of importance
for two reasons: first, because the slow onset of relief from
conventional medications leaves a window of vulnerability
for individuals suffering from severe depression or
suicidality; and second, because current antidepressant
treatments fail in approximately 25-50% of individuals
treated (Little, 2009; Nemeroff, 2007; Souery, Papakostas,
& Trivedi, 2006), and in some cases may actually worsen
outcomes (Gueorguieva, Mallinckrodt, & Krystal, 2011).
Even when there is clinical response to current
antidepressants, the results are only somewhat better than

placebo (Kirsch & Sapirstein, 1998; Kirsch et al., 2008;
Moncrieff & Kirsch, 2005), especially for individuals
whose depressive symptoms are mild to moderate
at baseline (Fournier et al., 2010). It even has been
suggested that the benefits actually conferred may be due
to the psychological impact of non-specific physiological
effects (Kirsch & Sapirstein, 1998; Moncrieff, 2007),
and in any case such benefits may decrease over time
(Goldberg, Privett, Ustun, Simon, & Linden, 1998).
While individuals with the most severe depression show
greater benefits from medication relative to placebo
(Fournier et al., 2010), possibly this is the result of a
lower response rate to placebo in such cases rather than
enhanced drug efficacy (Kirsch et al., 2008). With the
limited success of current pharmacological antidepressant
strategies and the paucity of progress in the development
of new antidepressant drugs (Hendrie & Pickles, 2013),
pharmacological treatment has stagnated. The poor longterm outcomes for current depression treatment (Fekadu
et al., 2009; Goldberg et al., 1998; Kiloh, Andrews, &
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Nielson, 1988; Tuma, 2000), together with its relatively
high incidence (Kessler et al., 2003) and great societal
impact (McKenna, Michaud, Murray, & Marks, 2005;
Murray & Lopez, 1997), suggest that new antidepressant
strategies could be of considerable value.
While there has been growing public interest
in the potential of ketamine, the robust nature of
ketamine as a stand-alone treatment for depression and
other psychiatric diagnoses has yet to be convincingly
demonstrated. Short-term relief lasting from minutes
to a few days has been the rule, particularly with single
ketamine sessions (Katalinic et al., 2013), and this may be
extremely important in crisis situations where immediate,
even if not sustained, relief can be lifesaving. When
administration is repeated and provided in concert with a
variety of psychotherapies supporting the sustained and/or
intermittent use of the drug, there has also been reported
success (e.g., Khorramzadeh & Lofty, 1973; Kolp et al.,
2014 [this issue]; Krupitsky & Grinenko, 1997). The jury
is still out, however, on long-term maintenance dosages
of of ketamine for treating depressions but, despite this
lack of clarity, ketamine as a Schedule III drug with
a long history of safe use has become a growing part of
the psychiatric arsenal with individuals and clinics—
including anesthesiologists—administering the substance
in varying ways (Ryan et al., 2014 [this issue]).
Characteristic of the increased popularity of
ketamine treatment has been a specific methodology
designed to minimize ketamine’s potentially powerful
psychedelic effects, which are nevertheless difficult
to eliminate entirely. The psychedelic properties of
ketamine may remain present to some degree, even
when administered in the small dosages typically used in
studies that attempt to establish its efficacy for depression.
Seeing these as undesirable appears to be based on the
assumption that such “side-effects” are both negative and
separable from its antidepressant properties.
Ketamine has been recognized for its psychedelic
properties since 1965, through underground use and a
few publications (cf. Jansen, 2004; Kolp et al., 2014 [this
issue]). The first study to intentionally examine ketamine’s
psychedelic effect at subanesthetic doses was published in
1985 by Golechha, Rao, and Ruggu, reporting on the
use of 1mg/kg administered intramuscularly (IM) in two
males, 51kg and 61kg respectively, with the stated purpose
of narcoanalysis. Early reports suggested an emotionally
beneficial effect from such doses, which are large enough
to produce psychedelic experiences that could be
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considered transformational. These often resulted in what
was sometimes called a psychedelic afterglow, tending
to last for significant periods of time after the ketamine
sessions, and suggesting an antidepressant effect. It
seems possible that such experiences may have led to the
subsequent exploration of ketamine as an antidepressant.
Later research has de-emphasized ketamine’s
psychedelic properties—perhaps considering these to be
a stigma that might impede its psychotherapeutic use.
Krystal, along with Charney and other colleagues (1994)
at the National Institute of Mental Health, deserve credit
for the development of what might be referred to as the
“NIMH protocol,” with publication of a paper examining
its sub-anesthetic effects. In this first paper from a group
with Charney as its principal investigator, psychedelic
effects were still recognized, even though considered as
undesirable. Krystal et al. (1994) reported that:
Ketamine (1) produced behaviors similar to the
positive and negative symptoms of schizophrenia;
(2) elicited alterations in perception; (3) impaired
performance on tests of vigilance, verbal fluency,
and the Wisconsin Card Sorting Test; (4) evoked
symptoms similar to dissociative states; and (5)
preferentially disrupted delayed word recall, sparing
immediate recall and post-distraction recall. (p. 199)
Research teams including Charney—illustrating
continuity in the development of this research—published
results from randomized, placebo-controlled, doubleblind studies of ketamine’s impact on major depression in
2000 (Berman et al.) and 2006 (Zarate et al.). These two
studies demonstrated rapid and robust antidepressant
response to a single dose of ketamine using the NIMH
protocol, with effect lasting 72 hours or more in 12 of
25 total patients; relapse occurred in all but two patients
in less than two weeks post ketamine infusion. By 2010
aan het Rot and colleagues, again including Charney,
had moved from a single dose of ketamine to a series of
six infusions administered over 12 days, each infusion at
the same dosage that had previously proven efficacious
in single-dose treatment. Response criterion was met by
nine of ten patients after the first infusion as well as after
the sixth. Patients who responded to the initial infusion
maintained their response for as long as they received
additional doses and for at least six days after that. Four
of nine patients relapsed less than 2 weeks post-ketamine
treatment. Eight of nine patients relapsed between 6 and
45 days, the average being 19 days, with one patient’s
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antidepressant effect lasting for more than three months.
Interestingly, aan het Rot et al (2010) designed this
study to be comparable with electroconvulsive therapy
(ECT)—which they noted also showed high relapse rates
in the month after discontinuation of shock therapy.
Krystal et al.’s (1994) initial report of the effects of
the NIMH protocol is markedly different from that offered
by aan het Rot et al. when the latter team replicated the
NIMH protocol in 2010. They commented, “Ketamine
elicited minimal positive psychotic symptoms. Three
patients experienced significant but transient dissociative
symptoms. Side effects during and after each ketamine
infusion were generally mild” (p. 139). Note that Krystal
et al.’s (1994) report of “positive and negative symptoms
of schizophrenia” (p. 199) changes to “positive psychotic
symptoms” in aan het Rot et al. (2010, p. 139); these were
now “minimal,” dissociative symptoms, were “transient”
and limited to a small subset of participants, and side
effects were “generally mild” (p. 139). This significant
shift in emphasis—little short of a reversal of findings—
occurred with the same drug, administered at the same
dose, with at least one principal investigator common to
both teams; apparently something else had changed.
As a further complication, in 2014 a team led
by Zarate (Luckenbaugh et al.)—first author on one of
the studies that included Charney—reported that in an
analysis of their data from 108 patients who received single
subanesthetic infusions of ketamine, the only variable in
their data predictive of a sustained antidepressant response
was the presence of dissociative side effects. Other
agents that, like ketamine, act as NMDA antagonists
but lack ketamine’s dissociative effects have thus far
been ineffective in producing antidepressant effects
(Zarate et al., 2013). Conversely, a study of the impact
of the dissociative anesthetic nitrous oxide on 20 subjects
diagnosed with treatment resistant depression yielded
outcomes similar to ketamine (Nagele et al., 2014). Such
findings raise the question of whether the antidepressant
effect comes from a specific chemical interaction in
the brain, whether a particular state of mind may have
some beneficial effect irrespective of the chemical used
to induce that state (cf. Moncrieff & Cohen, 2006), or
whether similar dissociative states may yield comparable
benefits through different in brain effects.
The lack of consistency in reporting sensory
effects of ketamine during IV administration of the
NIMH protocol provided incentive to undertake this
study analyzing participants’ phenomenal experiences of
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the dissociative effects of ketamine using the same dosage
rate and method of administration as the NIMH protocol.
This represented an effort to gather specific data on the
presence or absence, and the nature, of any psychedelic
symptoms as reported by Krystal et al. (1994), aan het
Rot et al. (2010), and others.
The Study
his study was designed to gather evidence regarding
the presence or absence of dissociative effects from
ketamine, as well as on the qualities of any such effects
and how they might compare with qualities at higher
doses, working with experienced ketamine users who
volunteered to receive doses consistent with the NIMH
intravenous (IV) ketamine protocol followed by the
Charney teams (Krystal et al., 1994; Collins et al., 2010).
Selected vital signs were measured at intervals, and
qualitative reports were collected after the experience. The
latter are situated in the tradition of qualitative research on
psychedelics, such as DMT, ayahuasca (Bouso, Fábregas,
Antonijoan, Rodriguez-Fornells, & Riba, 2013), and
marijuana (Lile et al., 2013); it is also resonant with the
new Johns Hopkins experienced users study currently
enrolling subjects by Griffiths (2015) and his group,
which randomizes 20 subjects to five experiences each of
18 different possible psychoactive substances and placebo.
Participants
Eight subjects with at least five prior ketamine
experiences at boluses of 50mg or higher, and with no
ketamine dependency or negative health effects from
ketamine use, were recruited by word of mouth for the
study. All but one of these had had more than 20 previous
ketamine experiences, with dosage ranging from boluses
of 50mg to 130mg; all reported a history of positive
and transformative experiences at the higher IM doses.
All participants shared a longitudinal awareness of their
own and others’ ketamine experiences over time—a
process years to decades in duration. In pre-intervention
interviews, participants expressed a sense of their lives
changing over time—with some depressive episodes,
relationship upheavals, and emotional difficulties—yet
each expressed a sense of gratitude and appreciation
for the transformative experience that had occurred
with ketamine use, affecting their lives and minds
predominantly in a positive manner. None reported
depression at the time of the study.
Measures
Blood pressure, pulse rate, oxygen saturation,
and respiratory rates were collected, and the Beck
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Depression Inventory (BDI; Beck, Steer, & Carbin, 1988)
was administered pre- and post-intervention. Qualitative
reports were gathered during and after the intervention,
and subjects discussed the experience in context of their
own previous ketamine use at higher dosages.
Procedure
As a first step, medical personnel took baseline
measures of blood pressure, pulse rate, and oxygen
saturation for each subject, and the BDI was administered.
Subsequently, but prior to ketamine administration,
subjects spent 15 minutes relaxing in silence. Ketamine
was then administered to subjects, who were lying
down, through IV saline drip at a dosage of 0.5 mg/kg
over 40 minutes. The intervention took place in a quiet
atmosphere, with gentle music deemed to have a “spiritual”
quality played throughout the process; the same music
was used for all subjects. Blood pressure, pulse rates,
oxygen saturation and respiration rates were assessed 20
minutes into the study and 20 minutes after completion
of the infusion. Subjective data were accumulated by nonparticipant administrators who charted, for each subject,
observations, periodic inquiries, assessment of mental state,
and degree of psychedelic effect observed and reported,
if any. Following completion of the IV infusion, subjects
spent an additional hour in quiet with communication
only as necessary. The BDI was completed again at the
end of this reflective period, and a copy was taken home
for completion on the following day. After the reflective
period, participants engaged in a group discussion.
Results
All eight subjects completed the experience
without complications. Return to baseline was reached
within 30 minutes to one hour following completion of the
infusion. All subjects were fully ambulatory at completion
of the infusion with some residual psychomotor slowing.
Two subjects reported mild nausea during the infusion.
Several subjects ate vigorously after completion of the onehour post infusion rest phase. One subject complained of
an unusual and moderately severe headache for her, which
began 3 hours after completion and lasted two hours.
Another subject reported mild headache of brief duration.
Pulse rate, oxygen saturation, and observed
respiratory rate. These measures did not change from
baseline during the course of ketamine administration.
Blood pressure. Blood pressure measurements
increased above baseline for all subjects: 20-30mm
systolic, and 6-20mm diastolic, falling rapidly by 20
minutes after completion of the infusion.
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BDI. There were no significant changes in BDI
score, but subjects were not depressed at the onset of the study.
Observations. Reported visual effects and
withdrawal from usual visual sensations were the primary
sensory effects. Auditory experience was mildly affected
if at all, and the tactile sense was not noticeably impacted.
Subjects remained responsive to auditory exchanges
and responded appropriately to promptings, though
at times more slowly and with reduced commentary.
Environmental awareness was clearly diminished.
Subjects who received higher doses of ketamine tended
to report deeper experiences, regardless of their weight.
Qualitative reports. Descriptive comments
during the experience included reports of relaxation,
pleasant sensation, decreased cognitive function, and
some disabling of ordinary capacities (Table 1). As
experienced users, subjects commented freely on what was
characterized as the triviality of the experience—a period
of “OK” relaxation and mildly increased inner awareness,
with little if any affective modulation. Subjects typically
expressed skepticism that ketamine could have sustained
antidepressant properties when administered at this dose
or in this manner, and consensus that the experience was
best described as a very partial break from ordinary states
of mind. Seven subjects indicated no desire to repeat
the experience. One female subject felt changed by the
experience, later reporting that she felt “emotionally very
well” for several weeks, with increased motivation; she
said she “would do it again.”
Participant discussion and evaluation. In
discussion, a consensus recommendation emerged
from the group: for threshold- and higher-dosage
transformative work, beginning with a 40-50mg IM
bolus, potentially in a series of sessions with higher
dosages if indicated with the number of sessions to be
determined by clinical practice; should occur in a closely
monitored psychotherapeutic setting.
Also informed by the group discussion, it was
suggested that goals of ketamine assisted psychotherapy
should include facilitating a transformative experience in
relationship to one’s own ego that would potentially have
as its effect the reduction of obsessions through some
breakage of continuity of afflictive mind, reformation
of consciousness, reevaluation of the past and, hence,
future prospects. In addition, there is the novelty and
uniqueness of an experiential state, one that, to paraphrase
participants, tends to produce a relaxation of that sense
of control that attempts to keep the mind from deviating
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Table 1. Notes on Participant Responses and Reports
Subject 1

At 5 minutes—“usual sensations” of beginning of a K experience; “warm and floating”; mild
At 20 minutes—“didn’t seem like 15 minutes have gone by”; building—“higher than 10 minutes ago”
not particularly psychological
At 35 minutes—not shamanic, not empathogenic, no disinhibition, no loss of intellectual function;
floaty, soft, diffuse sensations in body
10 minutes post-infusion—shouldn’t drive, but could; stayed pretty much in contact

Subject 2

At 15 minutes— “something happening,” metallic taste
At 35 minutes—very pleasant, “definitely K,” warm, no hallucinations, mindful, “paper baggy,” “crinkly,”
could read or make phone calls

Subject 3

No report during administration (highest dose, 50 mg). While not clinically depressed prior to trial,
had flat-ish affect
2 weeks afterwards—has felt emotionally very well. Baseline reclusiveness seems comfortable and
basic inertia is less compelling—a little more willing to get out of her chair
“Dose was pretty much perfect”—both out and in, aware and able to talk—and remember most of it;
reported that session seemed to go by faster than an hour; “I would do it again”

Subject 4

At 5 minutes—a little relaxation; cold hands
At 20 minutes—mildly relaxed, “krinkly paper bag feeling,” +2 of 4 (Shulgin scale); would not make
phone calls; “now I want to close my eyes”; slightly disabling—feel cognitively sloppy, a little drunk;
past experience with 50mg. ketamine lozenge was “stronger than this”
At 40 minutes—“paper bag tongue,” tinnitus. “I do not think this [treatment protocol] is advantageous
or preferred”

Subject 5

At 10 minutes—+2 of 4 (Shulgin scale); would rather keep eyes closed
At 20 minutes—“door almost open,” +2 (Shulgin scale)
At 25 minutes—“I definitely don’t want to open my eyes,” +2½ (Shulgin scale)
At 30 minutes—some nausea, “an ugly 2½” (Shulgin scale)
5 minutes post—“Whew!”; quite “stoned” and nauseated; “I’d never do this again. This is not an
anti-depressant!”

Subject 6

At 7 minutes—“something happening,” mild, metallic taste, +/- (Shulgin scale)
At 20 minutes—high, “loopy,” no hallucinations, “can’t let go of obsession”
At conclusion—”I’d not spend money for this”

Subject 7

At 5 minutes—comfortable, peaceful, “going flowey”
At 11 minutes—“very high,” smiley, numb hands
At 20 minutes—floating, eyes closed, “I don’t want to talk”
At finish—“laughy, bound in my chest,” with open eyes—fuzzy vision, peaceful, puffy eyelids,
can’t breathe deeply

Subject 8:

At 3 minutes—heaviness in head
At 5 minutes—floaty, relaxed, “a familiar falling feeling but very gentle”
At 20 minutes—“very, very relaxed,” “not particularly insightful, in my opinion—not conducive to
therapeutic insight”
At 35 minutes—very relaxed, less intense, “very dissolving,” could walk with support,
“couldn’t drive,” peaceful, very tuned into all sounds

from what one might believe to be conventional sanity. It
is possible that this relaxing effect might lead to a more
robust and enduring antidepressant response.
Discussion
Based on participant reports in this small group,
the intramuscular (IM) route of administration initially
appears to be safe, effective, and less burdened with a

medical context that includes additional and costly
technological infrastructure that is necessary when
administering ketamine intravenously. It is well known
from psychoactive research that a patient’s mood and
the setting in which that research is conducted may
have significant impact on the quality of the resultant
experience. In such treatments a medicalized context
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has the potential to create an alienating atmosphere that
may diminish beneficial effect (e.g., Fadiman & Kornfeld,
2013). Provision of IM ketamine offers the advantage
of administration in a comfortable office setting, with
appropriate safety measures available.
The effects of ketamine appear to be related both
to dose and to subject sensitivity, and only partially to body
weight. In this study dosage was based on body weight at
a rate of 0.5mg/kg. Subjects with greater body weight who
received higher dosages had more of an anesthetic/sensory
effect and reported deeper experiences. For example, a
female subject who reported significant positive effects
had the highest body weight, and received the highest
dose (50mg). This outcome is consistent with the
researcher’s experience that drug effect and body weight
are related but not linearly correlated. It is generally the
case with psychedelic and other psychoactive substances
that individuals have a range of sensitivities irrespective
of their actual weight, and that effects are the result of
multiple factors, so that a dose that produces intoxication
or profound experience in one individual may produce
little or no response in another.
Based on extensive experience with ketamine,
it is possible to suggest that the sensory effects obtained
with dosages used in the NIMH protocol are quite low
within the range of effects produced by sub-anesthetic
doses of ketamine. As ketamine dosage increases (as to a
lesser extent with nitrous oxide) the sensory inputs and
perceptual integrations of the senses are progressively
turned off at the cortical level, leaving consciousness more
and more subject to its own view, experience, and creativity.
This state of mind, increasingly separated from external
input, bears some similarity to a dream state or a near
death experience—a heightened experience of internal
consciousness with its own particular linkages fostered
by ketamine. Tactile and visual perception are affected at
doses of 30-40mg, and olfactory, gustatory, and auditory
senses typically shift beginning at around 50mg. As
dosage increases, penultimately, this unique consciousness
itself diminishes and there is increasing memory loss of the
experience—hence the limits on the amount of ketamine
that is evocative of the state. Conscious awareness is
significantly impacted at 150mg or higher, tending
toward anesthesia as dosage increases. Beyond a certain
dosage range this impact on consciousness is a self-evident
drawback for an assisted psychotherapy experience.
Antidepressant substance treatments can be
thought of in categories relating to effects on consciousness
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according to the schema I am elucidating below, each
illustrated by typical examples, based on my experience as
a psychiatrist:
•

•
•

•
•

•

Interruption of consciousness and breakage of
the stream—ECT, narcoanalysis and induced
sleep in a continuum to coma
Disruption of consciousness, mild—NIMH IV
protocol of ketamine
Disruption, ego dissolution, and transformation—higher dose subanesthetic ketamine
and other psychedelics
Direct shifting of mood and new experiences of
affect—MDMA and other empathogens
Slow shifting of affective and anxious/obsessional
states—conventional antidepressants such as
SSRIs
Potential affective smoothing, re-focus and
obsession release—marijuana

In this context, IV ketamine administration at
0.5mg/kg results in a mild disruption of consciousness,
with a temporary release from a depressed affective and
obsessional state; state shift usually does not persist
much beyond the immediate effect of the experience,
and ordinary mental states along with the habitual state
of depression tend to resume quickly. Small disruptions
in consciousness produce minor changes in the course of
depression, in part because humans tend to ruminate and
obsess, because character is hard to shift, because humans
have an ongoing but changing experience of external
conditions, because external conditions do not change
due to having a ketamine session, and because individuals
live in their own history and the history and culture of the
external environment.
As noted, Luckenbaugh et al. (2014) indicated that dissociative effects predicted a sustained
antidepressant response. Subjects in this study who were
experienced ketamine users received doses in accordance
with the NIMH protocol that produced relatively mild
dissociative symptoms, and most of these reported only
minimal beneficial impact. This is consistent with studies
that show the antidepressant effect at these low dose levels
to be short-lived.
Summary and Conclusion
The effects of ketamine are related to dose and
subject sensitivity. For the most part, the higher the dose,
no matter what the route of administration, the greater
the anesthesia and interference with sensory modes, the
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greater the perceived internal stimulation and isolation of
consciousness to mind-only phenomena.
The antidepressant effect of the NIMH IV
protocol tends to be short-lived and has only been extended
by repeated administration of IV infusions and by being
a component part of an extended psychotherapeutic
modality.
The rapid onset of action of ketamine as an
antidepressant appears to be due to its disruption of
ordinary consciousness and its anesthetic properties.
There is much more work to be done to elucidate a specific
antidepressant property of ketamine, separate from or
attached to its dissociative effects.
With the possibility that higher doses may
produce antidepressant and other positive effects that
are more robust and sustained than with the NIMH IV
protocol, further explorations of ketamine’s effectiveness
are highly desirable, given the potential benefits of
ketamine assisted psychotherapy Higher dosages will
certainly include a more psychedelic component than
occurs in administration of the NIMH IV protocol.
Not all ketamine experiences are positive and
easy (see Kolp et al., this issue). Potential use by any route
includes the possibility of having difficult experiences,
best served by presence in a supportive, safe setting.
With positive preparation and administration in a safe
and comfortable environment, given the physiological
safety of ketamine, subjects may well derive great benefits
from dissociative, altered state experiences. This has been
the case with the psilocybin work being done at Johns
Hopkins by Griffiths, Richards, McCann, and Jesse
(2006), and in the MDMA assisted psychotherapy work
reported by Mithoefer, Wagner, Mithoefer, Jerome, and
Doblin (2011) and the Multidisciplinary Association
for Psychedelic Studies (MAPS). One can apply similar
models for IM ketamine administration that would
constitute a ketamine assisted psychotherapy protocol,
without the encumbrances of IV administration and
hospital settings.
The fact that there are disparities in reports
about the efficacy of ketamine as an antidepressant at
doses used in the NIMH protocol, and the possibility
that higher doses may produce effects that are more
robust and sustained than current formulations, calls
for further explorations of ketamine’s effects—potential
antidepressant, personality transformation, antiobsession, amongst others. Higher dosages will certainly
include a more psychedelic component than occurs

aan het Rot, M., Collins, K. A., Murrough, J. W., Perez,
A. M., Reich, D. L., Charney, D. S., & Mathew,
S. J. (2010). Safety and efficacy of repeated-dose
intravenous ketamine for treatment-resistant
depression. Biological Psychiatry, 67, 139-145.
Beck, A. T., Steer, R. A., & Carbin, M. G. (1988). Psychometric properties of the Beck Depression Inventory:
Twenty-five years of evaluation. Clinical Psychology
Review, 8(1), 77-100. doi:10.1016/0272-7358(88)90050-5
Berman, R. M., Cappielo, A., Anand, A., Oren, D.
A., Heninger, G. R., Charney, D. S., & Krystal, J.
H. (2000). Antidepressant effects of ketamine in
depressed patients. Biological Psychiatry, 47, 351-354.
doi:10.1016/j.biopsych.2009.08.038
Bouso, J. C., Fábregas, J. M., Antonijoan, R. M., RodríguezFornells, A., & Riba, J. (2013). Acute effects of
ayahuasca on neuropsychological performance:
Differences in executive function between experienced
and occasional users. Psychopharmacology (Berlin),
230(3), 415-424. doi:10.1007/s00213-013-3167-9
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in administration of the NIMH IV protocol. With
positive preparation and administration in a safe and
comfortable environment, given the physiological safety
of ketamine, subjects can generally be expected to be able
to emotionally handle their experiences. This has been
the case with the psilocybin work being done at Johns
Hopkins by Griffiths, Richards, McCann, and Jesse
(2006), and in the MDMA assisted psychotherapy work
reported by Mithoefer, Wagner, Mithoefer, Jerome, and
Doblin (2011) and the Multidisciplinary Association for
Psychedelic Studies (MAPS). However, in rare instances
profound nadir experiences may also occur (see Kolp et
al., this issue). One can apply similar models for ketamine
administration that would constitute a ketamine assisted
psychotherapy protocol, without the encumbrances of IV
administration and hospital settings.
Limitations and Delimitations
The small sample size limits the validity of this
study, and qualitative results are not widely generalizable.
The fact that subjects were experienced ketamine users
may have biased their attitudes toward or perceptions
of the effects of the intervention. Participants were not
significantly communicative during intervention, so
qualitative reports were thin. Group discussion was not
recorded and the presence of the researcher in the group
discussion may have influenced the recommendations.
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